Features of Mild-to-Moderate COVID-19 Patients With Dysphonia

Lechien, J; Chiesa‐Estomba, Carlos Miguel; Cabaraux, Pierre; Mat, Quentin; Huet, Kathy; Harmegnies, Bernard; Horoi, Mihaéla; Bon, Serge D Le; Rodriguez, Alexandra; Dequanter, Didier; Hans, Stéphane; Crevier‐Buchman, Lise; Hochet, Baptiste; Distinguin, Léa; Chekkoury‐Idrissi, Younès; Circiu, Marta; Afia, Fahd El; Barillari, Maria Rosaria; Cammaroto, Giovanni; Fakhry, Nicolas; Michel, J.; Radulesco, Thomas; Martiny, Delphine; Lavigne, Philippe; Jouffe, Lionel; Descamps, Géraldine; Journé, Fabrice; Trecca, Eleonora M C; Hsieh, Julien Wen; Delgado, Irene López; Calvo‐Henríquez, Christian; Vergez, S.; Khalifé, Mohamad; Molteni, Gabriele; Mannelli, Giuditta; Cantarella, Giovanna; Tucciarone, Manuel; Souchay, Christel; Leich, Pierre; Ayad, Tareck; Saussez, Sven

doi:10.1016/j.jvoice.2020.05.012

Cited by 119 publications

(176 citation statements)

References 13 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…Third, some otolaryngological regions remain uninvestigated such as the vocal folds. The investigation of these remaining regions may shed further light on some recently reported unusual clinical phenomena such as severe dysphonia [44].…”

Section: Discussionmentioning

confidence: 90%

ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review

Lechien

Radulesco

Calvo‐Henríquez³

et al. 2020

Head and Neck Pathol

Self Cite

View full text Add to dashboard Cite

To review the data regarding the expression of angiotensin converting enzyme-2 (ACE2) and transmembrane protease serine-2 (TMPRSS2) in head and neck tissue. Scopus, Cochrane Library, Medrxiv, Google Scholar and PubMED/MEDLINE were searched by four independent investigators for studies investigating ACE2 or TMPRSS2 expressions in head and neck tissues. The following outcomes were considered: sample origin (animal versus human); detection method; anatomical location and cell types. PRISMA checklist and modified population, intervention, comparison, outcome, timing and setting (PICOTS) framework were used to perform the review. Of the 24 identified studies, 17 met our inclusion criteria. Thirteen studies were conducted during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. ACE2 and TMPRSS2 were expressed in oral, pharyngeal, sinusonasal human mucosa. The following cell types expressed ACE2: basal, apical, goblet, minor salivary, and endothelial cells. TMPRSS2 was found in goblet and apical respiratory cells. ACE2 and TMPRSS2 were found in the olfactory region, especially in sustentacular non-neural and neural stem cells. Animal studies suggested that ACE2 expression may vary regarding age. There was an important heterogeneity between studies in the methods used to detect ACE2 and TMPRSS2, leading to a potential identification bias. The SARS-CoV-2 receptors, ACE2 and TMPRSS2, are both expressed in many head and neck tissues, enabling the viral entry into the host organism.

show abstract

Section: Discussionmentioning

confidence: 90%

ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review

Lechien

Radulesco

Calvo‐Henríquez³

et al. 2020

Head and Neck Pathol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Seizure 20 Articles [39], [58], [60], [63], [101], [150], [166], [167], [168], [169], [170], [171], [172], [173], [174] (continued on next page) [56], [57], [58], [62], [69], [101], [182], [183], [198], [199], [200], [201], [202], [203], [204], [205], [206], [61], [207], [208], [209], [210], [211], [212] [56], [57], [58], [61], [62], [69], [200], [201] [203] [204], [205], [206],…”

Section: Seizure 17mentioning

confidence: 99%

Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic

Dorche

Huot

Osherov

et al. 2020

Journal of the Neurological Sciences

186

182

View full text Add to dashboard Cite

Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Several studies have been performed, focusing on understanding the acute respiratory syndrome and treatment strategies. However, there is growing evidence indicating neurological manifestations occur in patients with COVID-19. Similarly, the other coronaviruses (CoV) epidemics; severe acute respiratory syndrome (SARS-CoV-1) and Middle East respiratory syndrome (MERS-CoV) have been associated with neurological complications. Methods: This systematic review serves to summarize available information regarding the potential effects of different types of CoV on the nervous system and describes the range of clinical neurological complications that have been reported thus far in COVID-19. Results: Two hundred and twenty-five studies on CoV infections associated neurological manifestations in human were reviewed. Of those, 208 articles were pertinent to COVID-19. The most common neurological complaints in COVID-19 were anosmia, ageusia, and headache, but more serious complications, such as stroke, impairment of consciousness, seizures, and encephalopathy, have also been reported. Conclusion: There are several similarities between neurological complications after SARS-CoV-1, MERS-CoV and COVID-19, however, the scope of the epidemics and number of patients are very different. Reports on the neurological complications after and during COVID-19 are growing on a daily basis. Accordingly, comprehensive knowledge of these complications will help health care providers to be attentive to these complications and diagnose and treat them timely.

show abstract

“…For those diagnosed with mild to moderate COVID‐19, 27% reported dysphonia, and was more common in females and smokers (Lechien et al . 2020). Time to recovery is as yet unreported.…”

Section: Service Delivery/clinical Implicationsmentioning

confidence: 99%

COVID‐19 and ENT SLT services, workforce and research in the UK: A discussion paper

Patterson

Govender

Roe

et al. 2020

Intl J Lang & Comm Disor

View full text Add to dashboard Cite

Background The COVID‐19 pandemic and the UK government's subsequent coronavirus action plan have fundamentally impacted on every aspect of healthcare. One area that is severely affected is ear, nose and throat (ENT)/laryngology where speech and language therapists (SLTs) engage in a diverse range of practice with patients with a range of conditions, including voice disorders, airway problems, and head and neck cancers (HNCs). A large majority of these patients are in high‐risk categories, and many specialized clinical practices are vulnerable. In addition, workforce and research issues are challenged in both the immediate context and the future. Aims To discuss the threats and opportunities from the COVID‐19 pandemic for SLTs in ENT/laryngology with specific reference to clinical practice, workforce and research leadership. Methods & Procedures The relevant sections of the World Health Organisation's (WHO) health systems building blocks framework (2007) were used to structure the study. Expert agreement was determined by an iterative process of multiple‐group discussions, the use of all recent relevant policy documentation, and other literature and shared documentation/writing. The final paper was verified and agreed by all authors. Main Contribution The main threats to ENT/laryngology SLT clinical services include increased patient complexity related to COVID‐19 voice and airway problems, delayed HNC diagnosis, reduced access to instrumental procedures and inequitable care provision. The main clinical opportunities include the potential for new modes of service delivery and collaborations, and harnessing SLT expertise in non‐instrumental assessment. There are several workforce issues, including redeployment (and impact on current services), training implications and psychological impact on staff. Workforce opportunities exist for service innovation and potential extended ENT/SLT practice roles. Research is threatened by a reduction in immediate funding calls and high competition. Current research is affected by very limited access to participants and the ability to conduct face‐to‐face and instrumental assessments. However, research opportunities may result in greater collaboration, and changes in service delivery necessitate robust investigation and evaluation. A new national set of research priorities is likely to emerge. Conclusions & Implications The immediate impact of the pandemic has resulted in major disruption to all aspects of clinical delivery, workforce and research for ENT/laryngology SLT. It is unclear when any of these areas will resume operations and whether permanent changes to clinical practice, professional remits and research priorities will follow. However, significant opportunity exists in the post‐COVID era to re‐evaluate current practice, embrace opportunities and evaluate new ways of working.

show abstract

Features of Mild-to-Moderate COVID-19 Patients With Dysphonia

Cited by 119 publications

References 13 publications

ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review

ACE2 & TMPRSS2 Expressions in Head & Neck Tissues: A Systematic Review

Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic

COVID‐19 and ENT SLT services, workforce and research in the UK: A discussion paper

Contact Info

Product

Resources

About